{"created":"2023-05-15T09:41:13.998263+00:00","id":296,"links":{},"metadata":{"_buckets":{"deposit":"7a179d95-1b24-4553-aab0-7f3a0bfc5d77"},"_deposit":{"created_by":11,"id":"296","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"296"},"status":"published"},"_oai":{"id":"oai:kagawa-u.repo.nii.ac.jp:00000296","sets":["13:40"]},"author_link":["2712"],"item_10006_date_granted_11":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2017-12-27"}]},"item_10006_degree_grantor_9":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"香川大学"},{"subitem_degreegrantor_language":"en","subitem_degreegrantor_name":"Kagawa University"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"16201","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_10006_degree_name_8":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_10006_description_7":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Since breast cancer shows diversity in clinical behaviors, a standard therapy does not always lead to favorable outcomes.","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Materials and Methods: The expression statuses of candidate markers, including topoisomerase-II alpha (TOP2A), beta-tubulin (B-tub), and tissue inhibitor of metalloprotease-1 (TIMP-1), were immunohistochemically evaluated in 70 breast cancer tissues from 68 patients with advanced breast cancers receiving chemotherapy.","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Results: The response rates to anthracycline and taxane were 70.5% and 67.2%, respectively. Overall, 25.1% ± 29.7%, 8.32% ± 10.1%, and 16.37% ±17.5% of cancer cells in the tumors studied were positive for B-tub, TOP2A, and TIMP-1 expressions, respectively. However, positive molecule expression did not differ between patients who did and did not exhibit clinical responses to treatment. The proportion of TOP2A-positive cancer cells was significantly higher among anthracycline responders than among nonresponders in HR-negative cancer (15.4% ±17.5% vs. 2.0% ± 2.4%, respectively, P = 0.048), whereas TOP2A and TIMP-1 expression statuses did not differ in HR-positive cancer. When patients were stratified according to B-tub, TOP2A, or TIMP-1 expression statuses (B-tub ≥10% vs. <10%, TOP2A ≥5% vs. <5%, TIMP-1 ≤20% vs. >20%, respectively), the proportion of patients with ≥10% B-tub-positive cancer cells was significantly higher in taxane responders than in nonresponders (72.4% vs. 37.5%, respectively, P = 0.016). Anthracycline responders showed a trend to have a higher proportion of patients with either ≥5% TOP2A-positive cancer cells or ≤20% TIMP-1-positive cancer cells compared to nonresponders (86.7% vs. 61.5%, respectively, P = 0.066).","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Conclusion: Immunohistochemical TOP2A, TIMP-1, and B-tub expression analyses are expected to be useful for predicting tumor responses to chemotherapy.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10006_dissertation_number_12":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"甲第675号"}]},"item_10006_relation_15":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.4103/jcrt.jcrt_1053_16","subitem_relation_type_select":"DOI"}},{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://dl.ndl.go.jp/pid/11122656","subitem_relation_type_select":"URI"}}]},"item_10006_relation_22":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"29516929","subitem_relation_type_select":"PMID"}}]},"item_10006_relation_28":{"attribute_name":"論文ID（NAID）","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"500001069907","subitem_relation_type_select":"NAID"}}]},"item_10006_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright © 2018, Wolters Kluwer Medknow Publications","subitem_rights_language":"en"},{"subitem_rights":"This article is available under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike License (CC BY-NC-SA), which permits non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited. Permission only needs to be obtained for commercial use.","subitem_rights_language":"en","subitem_rights_resource":"https://creativecommons.org/licenses/by-nc-sa/4.0/"}]},"item_10006_text_30":{"attribute_name":"KEID","attribute_value_mlt":[{"subitem_text_value":"28446"}]},"item_10006_version_type_18":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_fa2ee174bc00049f","subitem_version_type":"P"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Norimura, Shoko","creatorNameLang":"en"},{"creatorName":"法村, 尚子","creatorNameLang":"ja"},{"creatorName":"ノリムラ, ショウコ","creatorNameLang":"ja-Kana"}],"familyNames":[{"familyName":"Norimura","familyNameLang":"en"},{"familyName":"法村","familyNameLang":"ja"},{"familyName":"ノリムラ","familyNameLang":"ja-Kana"}],"givenNames":[{"givenName":"Shoko","givenNameLang":"en"},{"givenName":"尚子","givenNameLang":"ja"},{"givenName":"ショウコ","givenNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2712","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"9000006805533","nameIdentifierScheme":"CiNii ID","nameIdentifierURI":"http://ci.nii.ac.jp/nrid/9000006805533"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-10-30"}],"displaytype":"detail","filename":"Med_A675.pdf","filesize":[{"value":"782.3 kB"}],"format":"application/pdf","licensetype":"license_10","mimetype":"application/pdf","url":{"label":"本文","objectType":"fulltext","url":"https://kagawa-u.repo.nii.ac.jp/record/296/files/Med_A675.pdf"},"version_id":"3eecc3d9-e64f-4065-8f0e-e3f80cd89b87"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-10-30"}],"displaytype":"detail","filename":"Med_A675_abstract.pdf","filesize":[{"value":"71.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"内容の要旨","objectType":"abstract","url":"https://kagawa-u.repo.nii.ac.jp/record/296/files/Med_A675_abstract.pdf"},"version_id":"543ce088-8241-4e07-9989-e9138b22f217"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-10-30"}],"displaytype":"detail","filename":"Med_A675_result.pdf","filesize":[{"value":"414.5 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"審査の結果の要旨","objectType":"other","url":"https://kagawa-u.repo.nii.ac.jp/record/296/files/Med_A675_result.pdf"},"version_id":"fc442e23-a4ff-4774-901a-0eb897a1ea09"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Anthracycline","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"beta-tubulin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"breast cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"predictive biomarker","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"taxane","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"tissue inhibitor of metalloprotease-1","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"topoisomerase-II alpha","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Candidate biomarkers predictive of anthracycline and taxane efficacy against breast cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Candidate biomarkers predictive of anthracycline and taxane efficacy against breast cancer","subitem_title_language":"en"}]},"item_type_id":"10006","owner":"11","path":["40"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2018-05-30"},"publish_date":"2018-05-30","publish_status":"0","recid":"296","relation_version_is_last":true,"title":["Candidate biomarkers predictive of anthracycline and taxane efficacy against breast cancer"],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2024-10-31T08:02:27.112273+00:00"}